Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

XERIS BIOPHARMA HOLDINGS, INC.

(XERS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Xeris Biopharma : , Merck in Collaboration Deal With Option to License ' XeriJect - Shares Jump

10/25/2021 | 09:41am EST


© MT Newswires 2021
All news about XERIS BIOPHARMA HOLDINGS, INC.
11/17SVB Leerink Starts Xeris Pharmaceuticals at Outperform With $6 Price Target
MT
11/10XERIS BIOPHARMA HOLDINGS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
11/10Xeris Biopharma Holdings, Inc. Provides Sales Guidance for the Year 2021
CI
11/10XERIS BIOPHARMA : Q3 Earnings Snapshot
AQ
11/10Earnings Flash (XERS) XERIS PHARMACEUTICALS Reports Q3 Revenue $11M, vs. Street Est of ..
MT
11/10Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
10/29Xeris Pharmaceuticals Shares Gain After HC Wainwright Starts Coverage at Buy
MT
10/29HC Wainwright Starts Xeris Pharmaceuticals at Buy With $4 Price Target
MT
10/25XERIS BIOPHARMA : Merck in Collaboration Deal With Option to License ' XeriJect - Shares J..
MT
10/08XERIS BIOPHARMA HOLDINGS, INC. : Other Events (form 8-K)
AQ
More news
Analyst Recommendations on XERIS BIOPHARMA HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 48,8 M - -
Net income 2021 -99,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,65x
Yield 2021 -
Capitalization 264 M 264 M -
Capi. / Sales 2021 5,42x
Capi. / Sales 2022 2,14x
Nbr of Employees 180
Free-Float 98,5%
Chart XERIS BIOPHARMA HOLDINGS, INC.
Duration : Period :
Xeris Biopharma Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,12 $
Average target price 6,25 $
Spread / Average Target 195%
EPS Revisions
Managers and Directors
Paul R. Edick Chairman & Chief Executive Officer
John Patrick Shannon President & Chief Operating Officer
Steven M. Pieper Chief Financial Officer
Ken Johnson Senior VP-Global Development & Medical Affairs
Steven Prestrelski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
XERIS BIOPHARMA HOLDINGS, INC.-56.91%251
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888